Prescription medication · Echinocandin Antifungal
caspofungin
Also sold as Cancidas. Caspofungin treats several types of fungal infections.
Data updated 2026-05-15
- 1,649
- FDA reports
- 6
- InteractionsFew interactions
- In shortage
- FDA status
What the data shows
caspofungin (Cancidas) is a prescription Echinocandin Antifungal, with 1,649 FDA adverse-event reports on file, with 6 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
caspofungin (Cancidas) is a prescription Echinocandin Antifungal. Caspofungin treats several types of fungal infections.
Caspofungin is an antifungal medicine. It fights fungal infections in your body.
Verify with FDA → · CMS NADAC pricing →
Drug Shortage Alert
caspofungin is currently listed as to be discontinued by the FDA. Affected manufacturer: Fresenius Kabi USA, LLC.
View all drug shortages →What it does
Caspofungin treats several types of fungal infections.
Common side effects
Diarrhea, Fever, Increased liver enzyme levels
Key warnings
Caspofungin can cause serious allergic reactions, including anaphylaxis.
The sections below are summarized in plain English from caspofungin's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Caspofungin stops fungi from growing. It does this by blocking a key part of the fungal cell wall. This causes the fungal cells to die.
Side Effects (from patient reports)
Based on 1,649 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for caspofungin, by number of reports
- Death
Death
223 reports
- Lung infection
Lung infection
200 reports
- Fever
Fever
196 reports
- Blood infection
Blood infection
193 reports
- Severe blood infection leading to organ damage
Severe blood infection leading to organ damage
175 reports
- Fever with low white blood cell count
Fever with low white blood cell count
163 reports
- Lungs can't provide enough oxygen
Lungs can't provide enough oxygen
132 reports
- Failure of multiple organs
Failure of multiple organs
129 reports
- Medicine interacts with another medicine
Medicine interacts with another medicine
122 reports
- Low platelet count
Low platelet count
116 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Serious Warnings
Caspofungin can cause serious allergic reactions, including anaphylaxis. If you have signs of an allergic reaction, stop taking caspofungin right away. Caspofungin can also affect your liver. Your doctor will monitor your liver function with blood tests.
Known Drug Interactions
7 DRUG INTERACTIONS Cyclosporine : In two adult clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of caspofungin. Caspofungin did not increase the plasma levels of cyclosporine. There were transient increases in liver ALT and AST when caspofungin and cyclosporine were co-administered.
Mechanism: Cyclosporine increases the levels of caspofungin in your blood and may cause temporary stress or irritation to your liver.
Other Inducers of Hepatic CYP Enzymes Adults : When caspofungin is co-administered to adult patients with other inducers of hepatic CYP enzymes, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, administration of a daily dose of 70 mg of caspofungin should be considered [see Dosage and Administration ( 2.5 ) and Clinical Pharmacology ( 12.3 )] . Pediatric Patients : When caspofungin is co-administered to pediatric patients with other inducers of hepatic CYP enzymes, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, administration of a daily...
Mechanism: Carbamazepine causes your liver to break down caspofungin faster than usual, which can lower the amount of medicine in your body.
Other Inducers of Hepatic CYP Enzymes Adults : When caspofungin is co-administered to adult patients with other inducers of hepatic CYP enzymes, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, administration of a daily dose of 70 mg of caspofungin should be considered [see Dosage and Administration ( 2.5 ) and Clinical Pharmacology ( 12.3 )] . Pediatric Patients : When caspofungin is co-administered to pediatric patients with other inducers of hepatic CYP enzymes, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, administration of a daily...
Mechanism: Phenytoin speeds up the way your liver processes caspofungin, which may reduce the medicine's ability to fight infection.
Other Inducers of Hepatic CYP Enzymes Adults : When caspofungin is co-administered to adult patients with other inducers of hepatic CYP enzymes, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, administration of a daily dose of 70 mg of caspofungin should be considered [see Dosage and Administration ( 2.5 ) and Clinical Pharmacology ( 12.3 )] . Pediatric Patients : When caspofungin is co-administered to pediatric patients with other inducers of hepatic CYP enzymes, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, administration of a daily...
Mechanism: Dexamethasone triggers your liver to clear caspofungin from your system more quickly than it normally would.
Telaprevir Decrease AUC by 92% Systemic Hormonal Contraceptives Prevention or Management: Advise patients to change to non-hormonal methods of birth control during rifampin therapy Estrogens Decrease exposure Progestins Anticonvulsants Phenytoin Administered with rifampin 450 mg daily Decrease exposure Antiarrhythmics Disopyramide Decrease exposure Mexiletine Decrease exposure Quinidine Decrease exposure Propafenone Decrease AUC by 50%–67% Tocainide Decrease exposure Antiestrogens Tamoxifen Decrease AUC by 86% Toremifene Decrease steady state concentrations of toremifene in serum...
Mechanism: Rifampin increases the activity of enzymes that break down other drugs, which reduces the amount of caspofungin available to fight infection.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
How long will I need to take caspofungin?
Can I take caspofungin with other medications?
What should I do if I experience side effects?
Will caspofungin interfere with my other health conditions?
Can caspofungin be used for viral infections?
Is there a generic version of caspofungin?
How will I know if caspofungin is working?
Can I drive or operate machinery while taking caspofungin?
What kind of solution is caspofungin mixed with?
What are the common side effects of caspofungin?
Does caspofungin interact with other medications?
What drug class is caspofungin?
What pregnancy or breastfeeding source fields are listed for caspofungin?
Is caspofungin currently in shortage?
Related Medications in Echinocandin Antifungal
Other drugs grouped near caspofungin - same-class peers and common alternatives.
acyclovir
Zovirax
Acyclovir is an antiviral medicine.
Compare with caspofungin →
albendazole
Albenza
Albendazole is a medicine that fights parasites.
Compare with caspofungin →
amphotericin B
Ambisome, Fungizone
Amphotericin B liposome is an antifungal medicine.
Compare with caspofungin →
anidulafungin
Eraxis
Eraxis is an antifungal medicine.
Compare with caspofungin →
atovaquone/proguanil
Malarone
Malarone is a drug used to prevent and treat malaria.
Compare with caspofungin →
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on caspofungin
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for caspofungin
The FDA label for caspofungin (sold under brand names such as Cancidas) classifies it as a prescription-only medication in the Echinocandin Antifungal class. Caspofungin treats several types of fungal infections. Official labeling lists 7 commonly reported side effects, including Diarrhea, Fever, Increased liver enzyme levels.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 1,649 voluntary reports. The database also lists 6 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated minor severity. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Shortage status: FDA Drug Shortages Database.
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: May 2, 2023
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages